10.12.2012 Views

Protein Protocols Protein Protocols

Protein Protocols Protein Protocols

Protein Protocols Protein Protocols

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Monitoring Glycoprotein Heterogeneity 905<br />

126<br />

Analysis of Glycoprotein Heterogeneity<br />

by Capillary Electrophoresis and Mass Spectrometry<br />

Andrew D. Hooker and David C. James<br />

1. Introduction<br />

The drive toward protein-based therapeutic agents requires both product quality and<br />

consistency to be maintained throughout the development and implementation of a<br />

production process. Differences in host cell type, the physiological status of the cell,<br />

and protein structural constraints are known to result in variations in posttranslational<br />

modifications that can affect the bioactivity, receptor binding, susceptibility to proteolysis,<br />

immunogenicity, and clearance rate of a therapeutic recombinant protein in<br />

vivo (1). Glycosylation is the most extensive source of protein heterogeneity, and many<br />

recent developments in analytical biotechnology have enhanced our ability to monitor<br />

and structurally define changes in oligosaccharides associated with recombinant proteins.<br />

Variable occupancy of potential glycosylation sites may result in extensive<br />

glycosylation macroheterogeneity in addition to the considerable diversity of carbohydrate<br />

structures that can occur at individual glycosylation sites, often referred to as<br />

glycosylation microheterogeneity. Variation within a heterogeneous population of<br />

glycoforms may lead to functional consequences for the glycoprotein product. Therefore,<br />

regulatory authorities such as the US Food and Drug Administration (FDA) and<br />

the Committee for Proprietary Medical Productions demand increasingly sophisticated<br />

analysis for biologics produced by the biotechnology and pharmaceutical industries<br />

(2). The FDA has described a “well-characterized biologic” as “a chemical entity whose<br />

identity, purity, impurities, potency and quantity can be determined and controlled.”<br />

The glycosylation of a recombinant protein product can be examined by:<br />

1. Analysis of glycans released by chemical or enzymatic means.<br />

2. Site-specific analysis of glycans associated with glycopeptide fragments following proteolysis<br />

of the intact glycoprotein.<br />

3. Direct analysis of the whole glycoprotein.<br />

A number of techniques are currently available to provide rapid and detailed analysis<br />

of glycan heterogeneity:<br />

1. High-pH anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD).<br />

2. Enzymatic analysis methods such as the reagent array analysis method (RAAM; 3,4).<br />

From: The <strong>Protein</strong> <strong>Protocols</strong> Handbook, 2nd Edition<br />

Edited by: J. M. Walker © Humana Press Inc., Totowa, NJ<br />

905

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!